ArticleCancers2022

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors.

Sophie L Gerritse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.